(Q44815207)

6 December 2017

title

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide (English)

1 reference

6 December 2017

Alexander Jetter

1

1 reference

6 December 2017

Martina Kinzig-Schippers

2

1 reference

6 December 2017

Andreas Skott

3

1 reference

6 December 2017

Andreas Lazar

4

1 reference

6 December 2017

Dorota Tomalik-Scharte

5

1 reference

6 December 2017

Julia Kirchheiner

6

1 reference

6 December 2017

Monika Walchner-Bonjean

7

1 reference

6 December 2017

Ursula Hering

8

1 reference

6 December 2017

Verena Jakob

9

1 reference

6 December 2017

Michael Rodamer

10

1 reference

6 December 2017

Wafaâ Jabrane

11

1 reference

6 December 2017

Dirk Kasel

12

1 reference

6 December 2017

Jürgen Brockmöller

13

1 reference

6 December 2017

Uwe Fuhr

14

1 reference

6 December 2017

Fritz Sörgel

15

1 reference

6 December 2017

publication date

25 March 2004

1 reference

European Journal of Clinical Pharmacology

6 December 2017

published in

1 reference

6 December 2017

volume

60

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

165-171

1 reference

Protection of DNA during preparative agarose gel electrophoresis against damage induced by ultraviolet light

6 December 2017

cites work

1 reference

12 December 2020

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

12 December 2020

Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9

1 reference

12 December 2020

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

1 reference

12 December 2020

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

1 reference

12 December 2020

Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes

1 reference

12 December 2020

Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects

1 reference

12 December 2020

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

12 December 2020

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

1 reference

12 December 2020

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes

1 reference

12 December 2020

Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.

1 reference

12 December 2020

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

1 reference

12 December 2020

Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily

1 reference

12 December 2020

10.1007/S00228-004-0754-Z

Identifiers

DOI

1 reference

6 December 2017

1 reference